Dual Action for Bausch + Lomb

Bausch + Lomb advances dry eye therapy to Phase 3 and reports positive Phase 1b results for investigational ocular pain treatment

1

Bausch + Lomb is advancing a dual-action dry eye drop combining lifitegrast and PFHO, moving to Phase 3 after Phase 2 results.
2

The dual-action therapy showed a significant reduction in corneal fluorescein staining at Day 15 compared to lifitegrast alone.
3

Bausch + Lomb's formulation uses over 50% less lifitegrast and is dosed at half the frequency of existing therapies.
4

BL1332, a TRPV1 antagonist, met its primary endpoint in a Phase 1b study, showing significant pain reduction in treated eyes.
5

BL1332 is now in Phase 2 trials for pain following photorefractive keratectomy, with results expected soon.

1